Back to Authors

Tachibana, Hirofumi

0000-0003-4820-2122

A5053378499 | I135598925

Mayo Clinic

Kyushu University

Citations 3

SphK1 inhibitor potentiates the anti‐cancer effect of EGCG on leukaemia cells

British Journal of Haematology | May 25, 2016 | Volume: 178 | Issue: 1 | Pages: 155-158

10.1111/bjh.14119 | PMID 27220679

Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKs

Molecular Cancer Therapeutics | August 11, 2015 | Volume: 14 | Issue: 10 | Pages: 2303-2312

10.1158/1535-7163.mct-15-0185 | PMID 26264277

Abstract Activation of acid sphingomyelinase (ASM) leads to ceramide accumulation and induces apoptotic cell death in cancer cells. In the present study, we demonstrate that the activation of ASM by targeting cancer-overexpressed 67-kDa laminin receptors (67LR) induces lipid raft disruption and inhibits receptor tyrosine kinase (RTK) activation in multiple myeloma cells. Sphingosine kinase 1 (SphK1), a negative regulator of ceramide accumulation with antiapoptotic effects, was markedly elevated in multiple myeloma cells. The silencing of SphK1 potentiated the apoptotic effects of the green tea polyphenol epigallocatechin-3-O-gallate (EGCG), an activator of ASM through 67LR. Furthermore, the SphK1 inhibitor safingol synergistically sensitized EGCG-induced proapoptotic cell death and tumor suppression in multiple myeloma cells by promoting the prevention of RTK phosphorylation and activation of death-associated protein kinase 1 (DAPK1). We propose that targeting 67LR/ASM and SphK1 may represent a novel therapeutic strategy against multiple myeloma. Mol Cancer Ther; 14(10); 2303–12. ©2015 AACR.
Vardenafil, a clinically available phosphodiesterase inhibitor, potentiates the killing effect of EGCG on CLL cells

British Journal of Haematology | September 24, 2014 | Volume: 168 | Issue: 4 | Pages: 610-613

10.1111/bjh.13135 | PMID 25250486